ArticleMolecular and clinical oncology2025
Clinical significance of cyclin-dependent kinase inhibitor 3 in hepatocellular carcinoma.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to determine the expression of cyclin-dependent kinase inhibitor 3 (CDKN3) as well as its clinical value in hepatocellular carcinoma (HCC) using bioinformatic analysis. The expression of CDKN3 in HCC and its correlation with HCC prognosis were analyzed using the UALCAN and SangerBox databases. The findings obtained from the UALCAN database were validated using immunohistochemistry. The Assistant for Clinical Bioinformatics database was employed for the unifactorial and multifactorial analyses regarding the correlation between CDKN3 and pathways, and the STRING database served for the correlation analysis between CDKN3 and proteins. The results revealed that CDKN3 expression increases in tumor tissues and corresponds with an increase in the tumor stage. CDKN3 crucially affects prognosis of patients with HCC and is an essential factor for the diagnosis and prognosis of this condition. CDKN3 expression in HCC is mainly related to pathways for DNA repair, fatty acid degradation, G2M checkpoints, MYC targets, selenium compound metabolism and tumor proliferation. The role of CDKN3 in HCC was found to be related to genes including
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.